Dapagliflozin vs Metformin: HbA1c, Weight and CV Effects
Metformin lowers HbA1c 1.0-1.5% with proven CV benefit; dapagliflozin lowers 0.5-0.8% but adds heart and kidney protection. No head-to-head trial exists.
Insulin Blood Sugar: Head-to-Head Comparisons
43 source-based articles maintained by the HealthRX.com Editorial Team.
43articles
3topic areas covered
May 26, 2026latest review
Insulin Blood Sugar: Head-to-Head Comparisons library
Showing 43 of 43 clinical reviews.
Dapagliflozin vs Metformin: Special Population Safety Guide
Dapagliflozin favors heart failure, CKD, and metformin-contraindicated patients; metformin stays first-line otherwise. Compare mechanisms, risks, and HbA1c effects.
Farxiga vs Metformin Cost and Access Head-to-Head
A clinical comparison of dapagliflozin (Farxiga) vs metformin on cost, access, efficacy, and safety, with trial data, guideline quotes, and a decision framework for prescribers and patients.
Farxiga vs Metformin Side Effects: A Head-to-Head Profile
A detailed clinical comparison of dapagliflozin (Farxiga) and metformin side-effect profiles, including cardiovascular outcomes, GI tolerability, and prescribing guidance from named trials and guidelines.
Farxiga vs Metformin: Combining the Two (Rationale + Risk)
A clinical comparison of dapagliflozin (Farxiga) and metformin for type 2 diabetes, including the evidence base for combining both agents, switching considerations, and safety data from major trials.
Farxiga vs Metformin: HbA1c, Kidney Cutoffs, and Switching
Metformin lowers HbA1c 1.0-1.5 points, Farxiga 0.5-0.8 but cuts CV death and HF risk 26%. Compare kidney cutoffs before switching or adding on.
Farxiga vs Metformin: Long-Term Durability of Blood Sugar Control
A head-to-head clinical comparison of dapagliflozin (Farxiga) and metformin for long-term glycemic durability, cardiovascular outcomes, weight, and real-world persistence in type 2 diabetes.
Farxiga vs Metformin: No Titration Needed vs Gradual Dosing
Farxiga starts at full 10 mg dose immediately; metformin needs 4-8 weeks uptitration. Both cut HbA1c about 1%, but side effects and dosing differ.
Farxiga vs Metformin: Real-World Evidence Comparison
A detailed, evidence-based comparison of dapagliflozin (Farxiga) and metformin for blood sugar control, weight, cardiovascular outcomes, and safety, using clinical trial and real-world data.
Farxiga vs Metformin: Which One and When to Switch
Farxiga and metformin work differently and are often combined, not swapped. See A1C effects, CV and kidney benefits, and how to switch safely.
Jardiance and Metformin Combo: How It Works Together
Jardiance and metformin combined cut HbA1c about 1.5 to 2.0 points via different mechanisms, adding heart and kidney protection metformin alone lacks.
Jardiance vs Farxiga Side Effects: Empagliflozin vs Dapagliflozin Head-to-Head
A detailed comparison of side-effect profiles for Jardiance (empagliflozin) and Farxiga (dapagliflozin), including genital infections, DKA risk, cardiovascular safety, and renal effects drawn from major clinical trials.
Jardiance vs Farxiga: Switching Between Empagliflozin and Dapagliflozin
Evidence-based comparison of Jardiance (empagliflozin) and Farxiga (dapagliflozin), including when and how to switch between SGLT2 inhibitors safely.
Jardiance vs Metformin in Special Populations: Head-to-Head
A clinical comparison of empagliflozin (Jardiance) and metformin across special populations including CKD, heart failure, elderly patients, and obesity. Evidence-based guidance on choosing, combining, or switching between these two type 2 diabetes agents.
Jardiance vs Metformin: Cost and Access Head-to-Head
A detailed comparison of Jardiance (empagliflozin) and Metformin covering drug costs, insurance coverage, generic availability, cardiovascular outcomes, and prescribing access for type 2 diabetes.
Jardiance vs Metformin: Head-to-Head Efficacy Compared
An evidence-based comparison of Jardiance (empagliflozin) and Metformin for type 2 diabetes, covering HbA1c reduction, cardiovascular outcomes, weight loss, and renal protection from major clinical trials.
Jardiance vs Metformin: Long-Term Durability of Blood Sugar Control
A deep clinical comparison of empagliflozin (Jardiance) vs metformin for long-term glycemic durability, drawing on EMPA-REG OUTCOME, UKPDS 34, and real-world cohort data to guide treatment decisions.
Jardiance vs Metformin: Real-World Evidence Comparison
A thorough comparison of empagliflozin (Jardiance) and metformin using real-world data, landmark trials, and current guidelines to help patients and providers make informed treatment decisions.
Jardiance vs Metformin: Side-Effect Profile Head-to-Head
A clinical comparison of empagliflozin (Jardiance) and metformin side effects, including GI tolerance, genital infections, cardiovascular outcomes, and weight changes from EMPA-REG OUTCOME and UKPDS 34.
Jardiance vs Metformin: Switching Between Them Safely
A clinical guide to switching between Jardiance (empagliflozin) and metformin, covering when to switch, how to transition, expected A1C changes, side effects, and what your prescriber considers before making the change.
Jardiance vs Metformin: Titration Speed and Tolerability Compared
A clinical comparison of empagliflozin (Jardiance) and metformin titration speed, tolerability, and glycemic outcomes, with trial data, dosing schedules, and guidance on switching.
Jardiance vs Metformin: What to Do When One Fails
A clinical comparison of empagliflozin (Jardiance) and metformin for type 2 diabetes, with evidence-based guidance on what to do when either drug stops working or causes intolerable side effects.
Lantus vs Tresiba: Switching Between Insulin Glargine and Insulin Degludec
Evidence-based comparison of Lantus (insulin glargine) and Tresiba (insulin degludec), including how to switch safely, dosing equivalence, hypoglycemia risk, and clinical trial data from ORIGIN and DEVOTE.
Metformin vs Lantus (Insulin Glargine): Head-to-Head Efficacy Comparison
Evidence-based comparison of metformin and insulin glargine (Lantus) for blood sugar control, including HbA1c reduction, weight effects, cardiovascular outcomes, and guideline recommendations.
Metformin vs Lantus (Insulin Glargine): Long-Term Durability of Blood Sugar Control
A direct clinical comparison of metformin and insulin glargine (Lantus) for long-term glycemic durability in type 2 diabetes, covering landmark trials, HbA1c outcomes, safety, and when switching is appropriate.
Metformin vs Lantus (Insulin Glargine): Real-World Evidence Comparison
A head-to-head look at metformin versus insulin glargine (Lantus) across clinical trials and real-world data, covering HbA1c reduction, weight, hypoglycemia risk, cardiovascular outcomes, and when clinicians switch between them.
Metformin vs Lantus (Insulin Glargine): Side-Effect Profile Head-to-Head
A clinical comparison of metformin and Lantus (insulin glargine) side effects, including GI symptoms, hypoglycemia risk, weight changes, and long-term safety data from UKPDS 34 and ORIGIN.
Metformin vs Lantus (Insulin Glargine): Special Populations Head-to-Head
A detailed clinical comparison of metformin and Lantus (insulin glargine) across special populations including elderly patients, CKD, pregnancy, obesity, and type 2 diabetes with cardiovascular disease.
Metformin vs Lantus (Insulin Glargine): Switching Between Them
Clinical comparison of metformin and Lantus (insulin glargine) for blood sugar control, including when and how to switch between them, trial evidence from UKPDS 34 and ORIGIN, and practical dosing guidance.
Metformin vs Lantus Cost and Access Head-to-Head
A clinical comparison of metformin and insulin glargine (Lantus) on cost, access, efficacy, and safety, with real trial data, pricing benchmarks, and prescribing guidance.
Metformin vs Lantus: Combining the Two (Rationale + Risk)
A clinical breakdown of metformin vs insulin glargine (Lantus): when to combine them, why the combination works, and the real risks patients and clinicians must weigh.
Metformin vs Lantus: Titration Speed and Tolerability Compared
A clinical comparison of metformin and insulin glargine (Lantus) covering titration speed, tolerability, glycemic outcomes, and when to switch or combine both agents.
Metformin vs Lantus: What to Do When One Fails
A clinical guide comparing metformin and insulin glargine (Lantus) for type 2 diabetes management, including what steps to take when either drug stops working.
Metformin vs Tresiba (Insulin Degludec): Cost and Access Head-to-Head
A clinical comparison of metformin and Tresiba (insulin degludec) covering cost, insurance access, efficacy data from UKPDS 34 and DEVOTE, and practical prescribing considerations for type 2 diabetes.
Metformin vs Tresiba (Insulin Degludec): Head-to-Head Efficacy Comparison
A clinical comparison of metformin and Tresiba (insulin degludec) for blood sugar control, covering HbA1c reduction, weight effects, hypoglycemia risk, and guideline positioning.
Metformin vs Tresiba (Insulin Degludec): Long-Term Durability of Response
A clinical comparison of metformin and insulin degludec (Tresiba) for long-term blood sugar control, covering durability of HbA1c reduction, cardiovascular safety, hypoglycemia risk, and when clinicians switch patients between the two.
Metformin vs Tresiba (Insulin Degludec): Real-World Evidence Comparison
A comparison of metformin and Tresiba (insulin degludec) drawing on UKPDS 34, DEVOTE, and real-world registry data, covering glycemic control, hypoglycemia risk, weight, cardiovascular outcomes, and when switching is appropriate.
Metformin vs Tresiba (Insulin Degludec): Side-Effect Profile Head-to-Head
A detailed comparison of metformin and Tresiba (insulin degludec) side effects, including GI tolerance, hypoglycemia risk, weight changes, and cardiovascular safety data from UKPDS 34 and DEVOTE.
Metformin vs Tresiba (Insulin Degludec): Special Populations Head-to-Head
A clinical comparison of metformin and Tresiba (insulin degludec) across special populations including elderly patients, CKD, pregnancy, and obesity. Evidence-based guidance prepared by the HealthRX.com Editorial Team.
Metformin vs Tresiba (Insulin Degludec): Switching Between Them
A clinical comparison of metformin and Tresiba (insulin degludec), including when and how to switch between them, efficacy data from UKPDS 34 and DEVOTE, and practical guidance for patients with type 2 diabetes.
Metformin vs Tresiba: Combining the Two (Rationale + Risk)
A comparison of metformin and insulin degludec (Tresiba), covering why combining them makes clinical sense, who qualifies, and what risks to monitor.
Metformin vs Tresiba: Titration Speed and Tolerability Compared
A clinical comparison of metformin and insulin degludec (Tresiba) covering titration protocols, tolerability, hypoglycemia risk, and when the two are combined or one replaces the other, prepared for qualified medical review.
Metformin vs Tresiba: What to Do When One Fails
A clinical deep-dive comparing metformin and insulin degludec (Tresiba), with guidance on when to switch, how to combine, and what the evidence says about sequencing these two cornerstone diabetes therapies.